PDCD1 and classic Hodgkin lymphoma: Pembrolizumab is a humanized anti-PD-1 IgG4 mAb approved by the FDA and EMA as monotherapy for patients with R/R cHL after ASCT failure or at least two prior lines of therapy if ASCT ineligible [47,48].